Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment

This study has been completed.
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: April 12, 2012
Last updated: October 31, 2013
Last verified: October 2013

The main objective of this study is to investigate the influence of mild, moderate and severe renal impairment on the pharmacokinetics and safety of BI 201335 in comparison to a control group with normal renal function after single dose of BI 201335.

Condition Intervention Phase
Hepatitis C
Drug: BI 201335
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pharmacokinetics, Safety and Tolerability of BI 201335 in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open-label, Parallel-group, Phase I Trial

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • AUC0-infinity (area under the concentration time curve of the analyte in plasma over the time interval from 0 to infinity) [ Time Frame: Up to 6 days ] [ Designated as safety issue: No ]
  • Cmax (maximum concentration of the analyte in plasma) [ Time Frame: Up to 6 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Changes from baseline in vital signs [ Time Frame: Up to 2 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline in electrocardiogram (ECG) results [ Time Frame: Up to 2 weeks ] [ Designated as safety issue: No ]
  • Changes from baseline laboratory measurements [ Time Frame: Up to 2 weeks ] [ Designated as safety issue: No ]
  • Number of participants with adverse events [ Time Frame: Up to 2 weeks ] [ Designated as safety issue: No ]

Enrollment: 32
Study Start Date: April 2012
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BI 201335 relevant treatment dose (A)
Capsule for oral administration
Drug: BI 201335
Relevant treatment dose capsule (A) for oral administration
Experimental: BI 201335 relevant treatment dose (B)
Capsule for oral administration
Drug: BI 201335
Relevant treatment dose capsule (B) for oral administration


Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

Male and female healthy subjects with normal renal function and subjects with impaired renal function in relatively good health

Exclusion criteria:

Any relevant deviation from healthy conditions for healthy volunteers or significant diseases other than renal impairment for the renal impaired subjects

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01580306

1220.58.1 Boehringer Ingelheim Investigational Site
Kiel, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim Identifier: NCT01580306     History of Changes
Other Study ID Numbers: 1220.58, 2011-005442-35
Study First Received: April 12, 2012
Last Updated: October 31, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases processed this record on July 27, 2015